Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Antimicrobials Effective for Inhibition of Enterohemorrhagic Escherichia coli Strains O26, O111, and O157 and Their Effects on Shiga Toxin Releases

  • Lee, John-Hwa (Veterinary Public Health, College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University) ;
  • Stein, Barry D. (Indiana Molecular Biology Institute, Indiana University)
  • Published : 2009.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The susceptibilities of major enterohemorrhagic Escherichia coli (EHEC) strains to antimicrobial agents and the cytotoxicity of these agents were examined using a total of 38 strains of E. coli O26, O111, and O157, which are the major serogroups of EHEC. Among the 38 strains, 35, 36, and 36 were susceptible to amikacin, imipenem, and norfloxacin, respectively. These antimicrobial agents were further examined to determine their cytotoxicity on Vero cells as well as their effect on the release of Shiga toxins along with trimethoprim/sulfamethoxazole. Each of the E. coli O26, O111, and O157 strains containing both the stx1 and stx2 genes were grown in the absence or presence of these agents at 1/4 minimal inhibitory concentration for 6 h, 12 h, and 18 h. At the concentrations used in this study, none of the agents significantly altered cell count compared with the control group. The level of cytotoxicity in the imipenem group was lower at 12 hand 18 h than their respective controls. In contrast, the level of cytotoxicity in cultures treated with trimethoprim/sulfamethoxazole, norfloxacin, and amikacin was increased. The strains were also examined for the release of Shiga toxins 1 and 2 following treatment with the agents, which were measured by the reversed passive latex agglutination (RPLA) method. The RPLA assay showed a suppression of release of Shiga toxin 2 in the strain cultures containing imipenem. These results indicate that imipenem may be a safe and effective agent for inhibition of these bacteria, which has clinical implications for the treatment of EHEC infections.

Keywords

References

  1. Allerberger, F., D. Rossboth, M. P. Dierich, S. Aleksic, H. Schmidt, and H. Karch. 1996. Prevalence and clinical manifestations of Shiga toxin-producing Escherichia coli infections in Austrian children. Eur. J. Clin. Microbiol. Infect. Dis. 15: 545-550 https://doi.org/10.1007/BF01709361
  2. Cordovez, A., V. Prado, L. Maggi, J. Cordero, J. Martinez, A. Misraji, et al. 1992. Enterohemorrhagic Escherichia coli associated with hemolytic-uremic syndrome in Chilean children. J. Clin. Microbiol. 30: 2153-2157
  3. Clinical and Laboratory Standards Institute (CLSI). 2008. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved Standard 3rd Ed. CLSI document M31-A3. Clinical and Laboratory Standards Institute, Wayne, PA
  4. Griffin, P. M. and R. V. Tauxe. 1991. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohaemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13: 60-98
  5. Herold, S., J. Siebert, A. Huber, and H. Schmidt. 2005. Global expression of prophage genes in Escherichia coli O157:H7 strain EDL933 in response to norfloxacin. Antimicrob. Agents Chemother. 49: 931-944 https://doi.org/10.1128/AAC.49.3.931-944.2005
  6. Holland, R. E., R. A. Wilson, M. S. Holland, V. Yuzbasiyan-Gurkan, T. P. Mullaney, and D. G. White. 1999. Characterization of $eae^+$ Escherichia coli isolated from healthy and diarrheic calves. Vet. Microbiol. 66:251-263 https://doi.org/10.1016/S0378-1135(99)00013-9
  7. Jeon, B., J. Jeong, G. Won, H. Park, S. Eo, H. Kang, J. Hur, and J. H. Lee. 2006. Prevalence and characteristics of Escherichia coli O26 and O111 from cattle in Korea. Int. J. Food Microbiol. 110: 123-126 https://doi.org/10.1016/j.ijfoodmicro.2006.01.035
  8. Jo, M., J. Kim, J. Lim, M. Kang, H. Koh, Y. Park, et al. 2004. Prevalence and characteristics of Escherichia coli O157 from major food animals in Korea. Int. J. Food Microbiol. 95: 41-49 https://doi.org/10.1016/j.ijfoodmicro.2004.01.016
  9. Laegreid, W. W., R. O. Elder, and J. E. Keen. 1999. Prevalence of Escherichia coli O157:H7 in range beef calves at weaning. Epidemiol. Infect. 123: 291-298 https://doi.org/10.1017/S0950268899002757
  10. Murakami, J., K. Kishi, K. Hirai, K. Hiramatsu, T. Yamasaki, and M. Nasu. 2000. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int. J. Antimicrob. Agents 15: 103-109 https://doi.org/10.1016/S0924-8579(00)00126-6
  11. Ostroff, S. M., P. I. Tarr, M. A. Neill, J. H. Lewis, N. Hargrett-Bean, and J. M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 160: 994-999 https://doi.org/10.1093/infdis/160.6.994
  12. Pavia, A. T., C. R. Nichols, and P. A. Blake. 1992. Hemolyticuremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons:Clinical and epidemiologic observations. J. Pediatr. 116: 544-551 https://doi.org/10.1016/S0022-3476(05)81600-2
  13. Prins, J. M., S. J. H. van Deventer, E. J. Kuijper, and P. Speelman. 1994. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob. Agents Chemother. 38: 1211-1218 https://doi.org/10.1128/AAC.38.6.1211
  14. Riley, L.W., R. S. Remis, S. D. Helgerson, H. B. McGee, J. G. Wells, B. R. Davis, et al. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:681-685 https://doi.org/10.1056/NEJM198303243081203
  15. Su, C. and L. J. Brandt. 1995. Escherichia coli O157:H7 infection in humans. Ann. Intern. Med. 123: 698-714 https://doi.org/10.7326/0003-4819-123-9-199511010-00009
  16. Sunde, M., K. Fossum, A. Solberg, and H. Sorum. 1998. Antibiotic resistance in Escherichia coli of the normal intestinal flora of swine. Microb. Drug Resist. 4: 289-299 https://doi.org/10.1089/mdr.1998.4.289
  17. Walterspiel, J. N., S. Ashkenazi, A. L. Morrow, and T. G. Cleary. 1992. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin 1. Infection 20: 25-29 https://doi.org/10.1007/BF01704889
  18. Wong, C. S., S. Jelacic, R. L. Habeeb, S. L. Watkins, and P. I. Tarr. 2000. The risk of hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342: 1930-1936 https://doi.org/10.1056/NEJM200006293422601
  19. Yoh, M. and T. Honda. 1997. The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Epidemiol. Infect. 119: 101-103 https://doi.org/10.1017/S0950268897007541
  20. Zhang, X., A. D. McDaniel, L. E. Wolf, G. T. Keusch, M. K. Waldor, and D. W. Acheson. 2000. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181: 664-670 https://doi.org/10.1086/315239

Cited by

  1. Effects of Subinhibitory Concentrations of Antimicrobial Agents onEscherichia coliO157:H7 Shiga Toxin Release and Role of the SOS Response vol.10, pp.9, 2009, https://doi.org/10.1089/fpd.2013.1510
  2. Versorgung und Behandlung von EHEC/HUS-Patienten : Erfahrungen und Perspektiven aus infektiologischer Sicht vol.56, pp.1, 2013, https://doi.org/10.1007/s00103-012-1577-1